The studies that will be described in Chapter 2 to 8, and which resulted in this thesis, aim to evaluate the effectiveness and safety of new HIV treatment strategies with INSTIs, especially DTG, in HIV-1 infected individuals. Furthermore, several aspects of cART-toxicity with dual NRTI backbones in combination with an INSTI, PI, or NNRTI are evaluated. The ultimate goal is a more individualized and patient-centered therapy by balancing virological and immunological efficacy with reduction of the risk of adverse events.

This thesis focuses on three issues.
Part 1 focuses on the effects of a switch from triple cART to DTG as maintenance monotherapy.
In part 2 the safety of initiating INSTI-containing cART in HIV late presenters with compromised immunity on the risk of IRIS is discussed.
Part 3 concentrates on aspects regarding safety of the NRTI backbone in INSTI, PI, or NNRTI containing cART and possibilities to further individualize HIV treatment.

, ,
A. Verbon (Annelies) , B.J.A. Rijnders (Bart) , C. Rokx (Casper)
Erasmus University Rotterdam
Department of Internal Medicine

Wijting, I. (2019, January 8). HIV Treatment Strategies – The role of integrase strand transfer inhibitors. Retrieved from